Cancer cell plasticity on targeted therapy
Ongoing · France
Source: EU Funding & Tenders Portal
Novel cancer molecular-targeted therapies allow to significantly prolong the survival of cancer patients. However, the inevitable acquisition of resistance mechanisms limits the clinical benefit of these treatments. To fully understand how resistance develops, it is crucial to better integrate tumor heterogeneity, cancer cell plasticity and microenvironment changes by applying cutting-edge single
- Status
- Under Construction
- Sector
- Government
- Location
- France
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Cancer cell plasticity on targeted therapy
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | ongoing |
Taiyo status | Under Construction |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Novel cancer molecular-targeted therapies allow to significantly prolong the survival of cancer patients. However, the inevitable acquisition of resistance mechanisms limits the clinical benefit of these treatments. To fully understand how resistance develops, it is crucial to better integrate tumor heterogeneity, cancer cell plasticity and microenvironment changes by applying cutting-edge single cell technologies directly on sequentially sampled biopsies from cancer patients. Additionally, to achieve deeper and longer-lasting clinical responses for cancer patients, we will need to target the rare drug-tolerant persister cancer cells. Samples collected before, during and after treatment will be used to fully describe the characteristics of the cells that are the source of genetic resistant variants that ultimately give rise to tumor relapses. By combining the establishment of patient-derived models, drug-screening of epigenetic inhibitors, transcriptomic and epigenetic characterization of persister cells we will aim to highlight their vulnerabilities. Finally, identify the driver mechanisms of genomic evolution by elucidating the link between oncogenic kinases and DNA repair pathways activity will be our innovative strategy to exploit putative susceptibilities to impeach the survival of resistant cells. The use of DNA repair substrate combined with CRISPR gene knockout will aim at confirming the value of targeting DNA repair pathways to profoundly transform the outcome of patients with metastatic cancer. Overall, by applying new technological breakthrough at the single cell level on patient biopsies, digging into the intrinsic nature of persister cells and taking advantages of DNA repair defects we will identify innovative treatment strategies to avoid the emergence of resistance in patients. |
Location
Country | France |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Government |
Article published date | 2025-12-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Government projects in France
- Projet 18e - Porte de Clignancourt
- Projet Broussais
- 250 premiers projets pour entretenir et rénover Paris
- Protocole d'accord RATP/Ville de Paris: création de 2000 logements d'ici 2024
- Chapelle Dubois Condorcet
- Les dix lauréats de l'appel à projets de l'Arc de l'innovation
- Projet 16e - 17e - Porte Maillot
- Sanofi Pasteur Vaccine Plant, Val De Reuil, France
